期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 31, 期 8, 页码 381-390出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2010.05.004
关键词
-
资金
- NIMH [T32 MH018870]
- NARSAD
- NIH [DA022413, MH54137]
- Lieber Center for Schizophrenia Research and Treatment
Dopamine D-2 receptor antagonism is a unifying property of all antipsychotic drugs in use for schizophrenia. While often effective at ameliorating psychosis, these drugs are largely ineffective at treating negative and cognitive symptoms. Increasing attention is being focused on the complex genetics of the illness and the signaling pathways implicated in its pathophysiology. We review targeted approaches for pharmacotherapy involving the glutamatergic, GABAergic and cholinergic pathways. We also describe several of the major genetic findings that identify signaling pathways representing potential targets for novel pharmacological intervention. These include genes in the 22q11 locus, DISCI, Neuregulin 1/ErbB4, and components of the Akt/GSK-3 pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据